Background, Basis of Presentation, Economic Dependency and Significant Accounting Policies: - Basis of Presentation thru Fair Value of Financial Instruments (Details) |
12 Months Ended | ||
---|---|---|---|
Feb. 28, 2022
USD ($)
item
|
Feb. 28, 2021
USD ($)
shares
|
Feb. 29, 2020
USD ($)
shares
|
|
Percentage of outstanding stock owned by the President and Chairman of the Board | 81.00% | ||
Number of antineoplaston drugs that have received FDA approval | item | 0 | ||
Economic Dependency | |||
Significant external revenue | $ 0 | $ 0 | |
Accumulated deficit | 125,838,483 | 124,861,827 | |
Losses incurred | $ 976,656 | 1,203,998 | |
Income Taxes | |||
Uncertain tax positions | $ 0 | $ 0 | |
Loss Per Common Share | |||
Warrants and stock options excluded from calculation of diluted loss per share (in shares) | shares | 1,600,000 | 1,600,000 | |
Fair Value of Financial Instruments | |||
Number of financial instruments held for trading purposes | item | 0 | ||
Minimum | |||
Economic Dependency | |||
Estimated useful lives | 5 years | ||
Maximum | |||
Economic Dependency | |||
Estimated useful lives | 10 years |
X | ||||||||||
- Definition Represents the number of antineoplaston drugs that have received FDA approval. No definition available.
|
X | ||||||||||
- Definition Represents the number of financial instruments held for trading purposes. No definition available.
|
X | ||||||||||
- Definition Represents the percentage interest of ownership held by the President of the Company, whom is also the Chairman of the Board. No definition available.
|
X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. No definition available.
|
X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of unrecognized tax benefits. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|